Latest news with #FreseniusKabiUSA
Business Wire
17-07-2025
- Business
- Business Wire
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Share This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Fresenius Kabi was recognized for its long-standing support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and a commitment to lower costs. Supplier Legacy Award winners are selected by Premier member committees and have a tenure of more than three years as a Premier contracted supplier. 'This award recognizes the commitment to service, innovation and collaboration by thousands of Fresenius Kabi employees from across our company,' said Arun Verma, President, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. 'It's especially gratifying to receive this award from a customer whose members make up more than 4,350 U.S. hospitals and health systems.' 'Fresenius Kabi supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value,' said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. 'We're honored to recognize Fresenius Kabi as a Supplier Legacy Award recipient.' The Supplier Legacy Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition (July 15-17, 2025). Premier has awarded Fresenius Kabi its Supplier Legacy Award in 2015, 2017, 2018, 2021, and now in 2025. In 2024, Premier also awarded Fresenius Kabi its Trailblazer Award, one of Premier's highest honors, recognizing a national Premier-contracted supplier that delivers innovative and scalable methods and technologies to accelerate clinical evidence into real-world practice. About Fresenius Kabi As a global health care company, Fresenius Kabi is Committed to Life. The company's products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company's I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of health care. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing health care solutions on a global scale. For more information, please visit To learn about U.S. career opportunities at Fresenius Kabi, visit us at and follow us on LinkedIn and Facebook.
Yahoo
27-05-2025
- Business
- Yahoo
Propofol Market to Reach USD 320.2 Million by 2034, Driven by Rising Demand for Anesthetic Solutions
Propofol Market Outlook (2025–2034) Luton, Bedfordshire, United Kingdom, May 27, 2025 (GLOBE NEWSWIRE) -- Market Overview The global propofol market is on a growth trajectory, projected to increase from USD 188.5 million in 2024 to USD 320.2 million by 2034, expanding at a compound annual growth rate (CAGR) of 5.5% during the forecast period. This growth is driven by increasing demand for anesthesia in surgical procedures, rising incidence of chronic diseases requiring hospitalization, and expanding use in intensive care units (ICUs). Advancements in drug formulations and heightened healthcare infrastructure in developing economies further fuel market expansion. However, concerns over misuse and stringent regulatory frameworks could act as limiting factors. Get a Sample PDF Brochure: Market Segmentation By Type Human Propofol Veterinary Propofol Human propofol dominates the market, accounting for the majority share due to its widespread application in surgeries, diagnostics, and critical care units. Veterinary propofol, while smaller in scale, is gaining momentum due to increased veterinary surgical procedures and pet care awareness. By Application Hospitals Clinics Other Hospitals represent the leading end-user segment, driven by the high volume of surgeries and ICU admissions. Clinics are also seeing increasing demand as outpatient procedures grow, particularly in cosmetic and minor surgical interventions. Regional Analysis of the Propofol Market (2025–2034) 1. North America Market Share: Largest regional market globally Key Countries: United States, Canada Drivers: High Volume of Surgeries: The U.S. performs the most surgical procedures globally, contributing significantly to propofol demand, especially in outpatient and inpatient care. Established Healthcare Infrastructure: Advanced hospital networks, critical care units, and ambulatory surgical centers maintain continuous demand for anesthetics. Regulatory Framework: Strict FDA oversight ensures high-quality standards in manufacturing, handling, and distribution, bolstering trust and adoption. Emergency & ICU Utilization: High incidence of chronic conditions like cardiovascular and respiratory diseases drives ICU admissions, where propofol is a primary sedative. Challenges: Increasing scrutiny on propofol misuse due to its history of off-label use and abuse. Rising healthcare costs may impact accessibility for underinsured populations. Country Insight – United States: Holds the largest global share of the propofol market. Key players like Fresenius Kabi USA, Pfizer, Baxter, and Hikma USA are based or operate extensively here. High investments in medical device integration and automated drug delivery systems are also boosting innovation. 2. Europe Market Share: Second largest globally Key Countries: Germany, France, UK, Italy, Spain Drivers: Aging Population: Europe has one of the oldest populations globally, resulting in higher surgical and ICU needs. Universal Healthcare Access: Public healthcare coverage ensures widespread access to anesthetic agents. Technological Advancements: Countries like Germany and the UK are leaders in surgical robotics and minimally invasive procedures, increasing use of sedatives like propofol. Challenges: Stringent EMA regulations delay new formulation approvals. Rising pressure to shift toward eco-friendly and biodegradable formulations to meet EU green goals. Country Insight – Germany: Home to B. Braun and other leading pharmaceutical firms producing hospital-grade propofol. Strong export hub for anesthetic drugs to Central and Eastern Europe. 3. Asia-Pacific Market Share: Fastest-growing region Key Countries: China, India, Japan, South Korea, Australia Drivers: Healthcare Expansion: Massive government and private sector investment in building hospitals and clinics, especially in India and China. Medical Tourism: Thailand, India, and Malaysia attract patients for affordable surgeries, driving demand for anesthetics. Economic Growth: Rising disposable income is boosting access to elective surgeries and private healthcare. Veterinary Healthcare Growth: Increasing demand for animal surgeries and care in markets like Japan and Australia contributes to segment expansion. Challenges: Inconsistent regulatory frameworks across countries delay cross-border drug approvals. Limited cold chain and storage infrastructure in rural areas restricts safe propofol distribution. Country Insight – India & China: Major hubs for generic propofol manufacturing and export. Local firms like Neon Labs and Bharat Serums are expanding R&D and manufacturing capacities. 4. Latin America Market Share: Moderate, with steady growth Key Countries: Brazil, Mexico, Argentina, Chile Drivers: Improving Healthcare Infrastructure: Ongoing investment in hospitals, ICUs, and surgical training. Non-Communicable Diseases (NCDs): High prevalence of diabetes, cardiovascular, and respiratory illnesses requiring surgical and ICU care. Government Health Programs: Expansion of public healthcare access under initiatives like Brazil's SUS (Unified Health System). Challenges: Economic volatility can impact healthcare budgets. Limited access in rural and underdeveloped regions delays elective procedures and ICU expansion. Country Insight – Brazil: Largest propofol consumer in Latin America due to a well-developed private and public healthcare sector. Increasing partnerships with multinational pharmaceutical firms for generic anesthetic supplies. 5. Middle East & Africa (MEA) Market Share: Smallest but growing steadily Key Countries: UAE, Saudi Arabia, South Africa, Egypt, Nigeria Drivers: Healthcare Modernization: Governments investing in smart hospitals and surgical capabilities (e.g., Vision 2030 in Saudi Arabia, UAE's Health Strategy). Medical Tourism: Countries like UAE and Jordan are becoming attractive destinations for cosmetic and orthopedic surgeries. Public-Private Partnerships (PPPs): Increased role of private players in supplementing government-led hospital expansion. Challenges: Political instability in parts of Africa hinders consistent healthcare delivery. Shortage of skilled anesthesiologists and intensivists limits high-volume surgery support in rural areas. Country Insight – UAE & Saudi Arabia: Rapidly building world-class surgical centers and attracting foreign medical professionals. Adopting digitized anesthesia monitoring and delivery systems in leading hospitals. Browse full Report - Competitive Landscape Fresenius Kabi B. Braun Maruishi Pharmaceutical Sandoz Aspen BBNWELL Hikma Teva Baxter Pfizer Market Dynamics Drivers Growing Demand for Surgical and Diagnostic Procedures The rise in both elective and emergency surgical interventions worldwide has significantly increased the demand for anesthetics like propofol. It is extensively used for induction and maintenance of general anesthesia in surgeries ranging from cardiac and neurological to cosmetic procedures. Additionally, diagnostic procedures such as endoscopy, colonoscopy, and MRI often require sedation, further boosting propofol usage. Increasing ICU Admissions and Emergency Care Requirements Propofol is widely used in intensive care units (ICUs) for sedation of mechanically ventilated patients. The increasing number of patients admitted for critical care—due to trauma, infectious diseases, or chronic conditions—has led to higher utilization. The COVID-19 pandemic further highlighted the importance of sedative agents in managing ventilated patients, creating long-term demand post-pandemic. Advancements in Anesthesia Formulations Pharmaceutical companies are investing in developing propofol formulations with improved stability, reduced side effects, and longer shelf life. Innovations such as lipid-free or nano-emulsion formulations reduce the risk of bacterial contamination and adverse reactions. These advancements aim to enhance safety, reduce pain on injection, and improve ease of administration. Expanding Healthcare Infrastructure in Emerging Economies Countries in Asia-Pacific, Latin America, and the Middle East are heavily investing in improving their healthcare systems. This includes the development of new hospitals, expansion of surgical facilities, and training of healthcare professionals. The improved access to surgical care and anesthesia services in these regions is directly contributing to higher demand for propofol. Restraints Risk of Abuse and Dependency Associated with Propofol Propofol is known for its potential misuse, particularly in non-medical settings or by healthcare professionals due to its rapid sedative effects and short half-life. Its abuse has been linked to several high-profile incidents and fatalities. This risk has led to stringent controls and hesitancy in widespread use outside monitored environments, limiting market potential. Stringent Regulatory and Compliance Requirements Propofol is classified under controlled substances in many countries. Regulatory approvals for new formulations or production facilities involve lengthy and expensive processes. Compliance with safety, storage, and transportation guidelines also imposes operational burdens on manufacturers and distributors. Potential Side Effects Limiting Usage in Certain Populations Despite its advantages, propofol can cause adverse effects such as hypotension, respiratory depression, and propofol infusion syndrome (a rare but potentially fatal complication). These risks necessitate careful monitoring and may lead to its restricted use in pediatric, elderly, or high-risk patient populations. Opportunities Rising Investments in Medical Tourism Countries such as India, Thailand, Turkey, and Mexico are becoming global hubs for medical tourism, attracting patients for cost-effective surgeries and procedures. With more international patients undergoing surgical treatments in these regions, the demand for reliable anesthesia agents like propofol is on the rise. Development of Novel Drug Delivery Methods Innovations such as target-controlled infusion (TCI) systems and patient-controlled sedation (PCS) are transforming the way anesthetics are delivered. These systems enhance precision, minimize drug wastage, and improve patient safety, thereby creating opportunities for advanced propofol products tailored for these technologies. Expansion of Veterinary Healthcare Services The rising expenditure on pet healthcare and the increase in veterinary surgical procedures are opening up new avenues for veterinary-grade propofol. Growing awareness and the humanization of pets are further boosting demand for safe and effective anesthetic agents in veterinary medicine. Increased Focus on Minimally Invasive Surgeries The shift towards outpatient and minimally invasive procedures, such as laparoscopic and robotic surgeries, necessitates fast-acting anesthetics with quick recovery times. Propofol's pharmacokinetic profile makes it ideal for such procedures, positioning it as the anesthetic of choice in ambulatory surgical centers. Buy Now : Challenges Regulatory Delays in Drug Approvals The time-consuming nature of regulatory approvals for new drug formulations or manufacturing units can slow down market entry and expansion. Companies often face delays due to complex documentation, clinical trial requirements, and evolving regulatory standards, especially when entering new markets. Supply Chain Constraints and Raw Material Availability Disruptions in the global supply chain—exacerbated by geopolitical conflicts, pandemics, or raw material shortages—can impact the consistent production and distribution of propofol. High dependence on specific ingredients like lipid emulsions and specialized packaging adds to the vulnerability of supply logistics. Ethical Concerns Related to Off-Label or Misuse The off-label use of propofol for non-anesthetic purposes, such as insomnia treatment or recreational use, raises ethical and legal issues. Media scrutiny and public concern surrounding misuse cases can damage brand reputation and trigger stricter enforcement, thereby limiting broader adoption. Company-Specific Recent Developments in the Propofol Market 1. Fresenius Kabi (Germany/Global) Key Focus: Propofol formulation innovation, global expansion, supply chain optimization Recent Initiatives: Product Innovation: Fresenius Kabi has developed advanced propofol formulations such as Propoven 2%, which was granted Emergency Use Authorization (EUA) by the U.S. FDA during the COVID-19 pandemic to address drug shortages. The company is enhancing formulations to reduce lipid content, mitigate injection site pain, and improve emulsion stability, a common issue in older formulations. Regulatory Milestones: Actively collaborating with the FDA and EMA for compliance in labeling, adverse event reporting, and improving pharmacovigilance systems. Implementing tamper-evident packaging and anti-diversion features in anesthetic product lines. Manufacturing Expansion: Expanded production capacity at its U.S. plant in Melrose Park, Illinois, specifically for critical injectable drugs including propofol. Strengthening presence in Asia-Pacific and Latin America to capture rising healthcare demand. 2. Hikma Pharmaceuticals (UK/Jordan-based multinational) Key Focus: Generic anesthetics, injectable growth strategy, cost-efficient alternatives Recent Initiatives: Generic Propofol Launches: Hikma launched Propofol Injectable Emulsion USP (10 mg/mL) in the United States, expanding its generics portfolio and providing a lower-cost alternative to branded products. Offering single-dose and multi-dose vials, catering to hospitals' and clinics' procurement preferences. Strategic Supply Chain Strengthening: Partnering with contract development and manufacturing organizations (CDMOs) to ensure stable API supply and mitigate raw material shortages. Focused on securing long-term tenders with health systems in the Middle East, North Africa, and Europe. FDA Compliance & Innovation: Implemented real-time batch quality tracking and is enhancing its cleanroom infrastructure to comply with evolving U.S. cGMP standards for injectables. 3. B. Braun Melsungen AG (Germany) Key Focus: Hospital-oriented anesthetics portfolio, sustainable packaging Recent Initiatives: Expanded its propofol product line under the brand Narcofol, targeting both surgical and intensive care applications. Focusing on ecological packaging and disposal systems to align with sustainable medical practices and hospital waste management standards. Investing in automated production lines for aseptic fill-finish operations, aimed at improving quality consistency and scalability. 4. Pfizer Inc. (USA) Key Focus: Branded anesthesia solutions, hospital partnerships Recent Initiatives: Marketed propofol under the Diprivan brand, a gold-standard reference product in hospital anesthetics. Working on next-generation sedation protocols incorporating AI-assisted monitoring and smart delivery systems. Participating in global forums to shape regulatory standards for safe anesthetic usage and monitoring in ICUs. 5. Baxter International Inc. (USA) Key Focus: Hospital automation, critical care drug delivery Recent Initiatives: While not a core manufacturer of propofol, Baxter integrates propofol within its automated infusion systems and ICU monitoring devices. Collaborating with pharmaceutical companies to co-develop closed-loop anesthesia systems using propofol as a primary agent. 6. Bharat Serums and Vaccines Ltd (India) Key Focus: Expanding injectable anesthetics in emerging markets Recent Initiatives: Launched propofol formulations under its anesthesia division for domestic hospitals and is exploring South Asian export markets. Leveraging India's manufacturing cost advantage to supply low-cost anesthetics to developing countries through government procurement schemes. 7. Neon Laboratories (India) Key Focus: Budget-conscious hospitals, bulk procurement supply Recent Initiatives: A major supplier to Indian public hospitals, Neon has ramped up local propofol production capacity and is pursuing WHO prequalification for international tenders. Developing veterinary-grade propofol formulations to tap into the animal healthcare segment. This report is also available in the following languages : Japanese (プロポフォール市場), Korean (프로포폴 시장), Chinese (丙泊酚市场), French (Marché du propofol), German (Propofol-Markt), and Italian (Mercato del Propofol), etc. Get a Sample PDF Brochure: More Related Reports: Celecoxib API Market The global market value for Celecoxib API (Active Pharmaceutical Ingredient) is estimated to reach approximately $700 million. The market is projected to expand significantly during the forecast period from 2025 to 2034, reaching an estimated value of $1.2 billion by 2034. This growth translates to a Compound Annual Growth Rate (CAGR) of around 6.0%, driven by increasing demand for non-steroidal anti-inflammatory drugs (NSAIDs), particularly for pain management and chronic inflammatory conditions. Pharmaceutical CDMO Market The pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is poised for significant growth, with an estimated market value of approximately $40 billion in 2024. The sector is projected to surge to around $75 billion by 2034, driven by increasing demand for biopharmaceuticals and tailored drug development services. Polydeoxyribonucleotide PDRN Market The global Polydeoxyribonucleotide (PDRN) market is poised for significant growth, currently valued at approximately $280 million in 2024. Forecasts predict the market will reach around $600 million by 2034, driven by increasing applications in regenerative medicine and cosmetic dermatology. This translates to a compound annual growth rate (CAGR) of about 8.3% during the period from 2025 to 2034. Dental Anesthesia Market The global dental anesthesia market is projected to reach approximately $1.5 billion in value by 2024, driven by the increasing prevalence of dental disorders and the rising demand for cosmetic dental procedures. Over the forecast period from 2025 to 2034, the market is expected to grow, reaching an estimated value of $2.5 billion. This indicates a Compound Annual Growth Rate (CAGR) of about 5.5%. Viscosupplementation Injection Market The global viscosupplementation injection market is valued at approximately $4.2 billion. It is poised for significant growth, with a projected market value reaching around $7.9 billion by 2034, driven by an increasing geriatric population and a rising prevalence of osteoarthritis and sports-related injuries. The market is expected to expand at a Compound Annual Growth Rate (CAGR) of about 6.7% during the forecast period from 2025 to 2034. Pharmaceutical Aseptic Fill & Finish CMO Market The global Pharmaceutical Aseptic Fill & Finish Contract Manufacturing Organization (CMO) market is valued at approximately $5.2 billion in 2024, with a projected growth trajectory leading to around $9.3 billion by 2034. This forecast indicates a Compound Annual Growth Rate (CAGR) of approximately 6.1% from 2025 to 2034. Pharmaceutical Aseptic Filling Services Market The global pharmaceutical aseptic filling services market is valued at approximately $5.2 billion in 2024. This market is expected to experience robust growth, reaching an estimated $9.2 billion by 2034, driven by increasing demand for biologics and sterile pharmaceuticals. The anticipated Compound Annual Growth Rate (CAGR) during the forecast period from 2025 to 2034 is projected at 6.1%. Zoladex Market The global Zoladex market, valued at approximately USD 1.8 billion in 2024, is poised for significant growth over the next decade, with projections estimating the market to reach around USD 3.5 billion by 2034. This growth represents a robust Compound Annual Growth Rate (CAGR) of 7.1% from 2025 to 2034. Alinia nitazoxanide Market The global market for Alinia (nitazoxanide) is valued at approximately $450 million. This market is projected to experience significant growth, reaching an estimated $850 million by 2034, reflecting a Compound Annual Growth Rate (CAGR) of around 6.6% during the forecast period from 2025 to 2034. Intravitreal Injectable Market The global intravitreal injectable market is valued at approximately $9.1 billion in 2024, driven by a surge in age-related macular degeneration and diabetic retinopathy cases. The market is expected to grow, reaching an estimated $15.3 billion by 2034, reflecting increasing demand for innovative therapies. This represents a Compound Annual Growth Rate (CAGR) of approximately 5.3% during the forecast period from 2025 to 2034. Pharmaceutical Blister Tooling Market The global pharmaceutical blister tooling market is valued at approximately $3.5 billion. Forecast projections indicate a compound annual growth rate (CAGR) of around 6.2%, estimating the market to reach about $5.6 billion by 2034. Pharma-Grade Hyaluronic Acid Market The global pharma-grade hyaluronic acid market is valued at approximately $1.7 billion in 2024 and is projected to reach around $3.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period of 2025 to 2034. L-Carnosine Market The global L-Carnosine market is valued at approximately $80 million, with strong growth anticipated due to increasing recognition of its potential health benefits, such as anti-aging and neuroprotective properties. Over the forecast period from 2025 to 2034, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.2%, reaching an estimated value of $190 million by 2034. Ketorolac Injection Market The global ketorolac injection market is valued at approximately $550 million in 2024 and is projected to reach around $850 million by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of about 4.2% during the forecast period from 2025 to 2034. Pharmaceutical Glass Market The global pharmaceutical glass market is valued at approximately $7.5 billion in 2024, with a projected growth trajectory that aims to reach around $12 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 5% during the forecast period from 2025 to 2034. Zeuterin Market The global Zeuterin market is anticipated to reach a valuation of approximately $200 million in 2024, driven by increased awareness of humane animal population control methods and rising demand from veterinary practices. The forecast period from 2025 to 2034 is expected to see substantial growth, with projections indicating a market value of around $350 million by 2034. Injectable Anticoagulants Market The global injectable anticoagulants market is valued at approximately $26 billion in 2024 and is projected to reach around $43 billion by 2034. This growth represents a compound annual growth rate (CAGR) of about 5.2% during the forecast period from 2025 to 2034. Eosinophilic Asthma Treatment Future Trends The global eosinophilic asthma treatment market is poised for significant growth, with a market value estimated at approximately $5.8 billion in 2024. Projections indicate that this market could reach around $9.7 billion by 2034, reflecting an impressive Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period from 2025 to 2034. 7-Aminocephalosporanic Acid 7-ACA Market The global market for 7-Aminocephalosporanic Acid (7-ACA) is valued at approximately $1.2 billion in 2024, driven by increasing demand in the pharmaceutical industry, particularly for cephalosporin antibiotics. The market is projected to reach around $2.5 billion by 2034, reflecting significant growth. This growth translates to a Compound Annual Growth Rate (CAGR) of approximately 7.5% during the forecast period from 2025 to 2034. OAB Treatment Market The global overactive bladder (OAB) treatment market is poised to reach an estimated value of $3.5 billion in 2024, driven by increasing prevalence rates of OAB among aging populations and heightened awareness of treatment options. The market is projected to expand significantly, with an anticipated compound annual growth rate (CAGR) of 7.2% from 2025 to 2034, potentially reaching a value of approximately $6.4 billion by 2034. CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@
